相似文献
1
Improving the biomarker pipeline to develop and evaluate cancer screening tests.
J Natl Cancer Inst. 2009 Aug 19;101(16):1116-9. doi: 10.1093/jnci/djp186. Epub 2009 Jul 2.
2
Evaluation of serum-based cancer biomarkers: a brief review from a clinical and computational viewpoint.
Crit Rev Oncol Hematol. 2015 Feb;93(2):103-15. doi: 10.1016/j.critrevonc.2014.10.002. Epub 2014 Oct 14.
3
Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.
PLoS Med. 2008 Aug 19;5(8):e170. doi: 10.1371/journal.pmed.0050170.
4
Cancer biomarkers: can we turn recent failures into success?
J Natl Cancer Inst. 2010 Oct 6;102(19):1462-7. doi: 10.1093/jnci/djq306. Epub 2010 Aug 12.
5
Serum ceruloplasmin as a diagnostic marker of cancer.
Cancer Lett. 1997 Dec 23;121(2):139-45. doi: 10.1016/s0304-3835(97)00340-6.
6
Early reporting for cancer screening trials.
J Med Screen. 2008;15(3):122-9. doi: 10.1258/jms.2008.007058.
7
[Clinical studies beyond the German Drug Law. Studies for evaluating diagnostic tests].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009 Apr;52(4):425-32. doi: 10.1007/s00103-009-0825-5.
8
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
J Natl Cancer Inst. 2001 Oct 3;93(19):1458-64. doi: 10.1093/jnci/93.19.1458.
9
[Clinical use and evolution of circulating biomarkers in the era of personalized oncology: From protein markers to bioclinical scores].
Bull Cancer. 2022 Feb;109(2):151-169. doi: 10.1016/j.bulcan.2021.11.010. Epub 2022 Jan 7.
10
Detection of colorectal neoplasia: Combination of eight blood-based, cancer-associated protein biomarkers.
Int J Cancer. 2017 Mar 15;140(6):1436-1446. doi: 10.1002/ijc.30558.
引用本文的文献
1
Designing cancer screening trials for reduction in late-stage cancer incidence.
Biometrics. 2024 Jul 1;80(3). doi: 10.1093/biomtc/ujae097.
2
Prediagnostic evaluation of multicancer detection tests: design and analysis considerations.
J Natl Cancer Inst. 2024 Jun 7;116(6):795-799. doi: 10.1093/jnci/djae050.
3
A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study.
Mol Cancer. 2022 Feb 11;21(1):44. doi: 10.1186/s12943-022-01507-x.
4
Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening.
Biomark Insights. 2020 Aug 4;15:1177271920946715. doi: 10.1177/1177271920946715. eCollection 2020.
5
Nested case-control data analysis using weighted conditional logistic regression in The Environmental Determinants of Diabetes in the Young (TEDDY) study: A novel approach.
Diabetes Metab Res Rev. 2020 Jan;36(1):e3204. doi: 10.1002/dmrr.3204. Epub 2019 Jul 31.
6
Study Design Considerations for Cancer Biomarker Discoveries.
J Appl Lab Med. 2018 Sep;3(2):282-289. doi: 10.1373/jalm.2017.025809.
7
Cancer Screening Markers: A Simple Strategy to Substantially Reduce the Sample Size for Validation.
Med Decis Making. 2019 Feb;39(2):130-136. doi: 10.1177/0272989X18819792. Epub 2019 Jan 18.
8
Validation of Biomarkers for Early Detection of Pancreatic Cancer: Summary of The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop.
Pancreas. 2018 Feb;47(2):135-141. doi: 10.1097/MPA.0000000000000973.
9
Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.
Am J Respir Crit Care Med. 2017 Oct 1;196(7):e15-e29. doi: 10.1164/rccm.201708-1678ST.
10
Direct and multiplex quantification of protein biomarkers in serum samples using an immuno-magnetic platform.
Chem Sci. 2016 Apr 21;7(4):2695-2700. doi: 10.1039/c5sc04115e. Epub 2016 Jan 4.
本文引用的文献
1
Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats.
BMC Cancer. 2009 Mar 23;9:89. doi: 10.1186/1471-2407-9-89.
2
Early reporting for cancer screening trials.
J Med Screen. 2008;15(3):122-9. doi: 10.1258/jms.2008.007058.
3
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.
J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8. doi: 10.1093/jnci/djn326. Epub 2008 Oct 7.
4
Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting.
Am J Epidemiol. 2008 Jul 1;168(1):89-97. doi: 10.1093/aje/kwn099. Epub 2008 May 13.
5
Theories of carcinogenesis: an emerging perspective.
Semin Cancer Biol. 2008 Oct;18(5):372-7. doi: 10.1016/j.semcancer.2008.03.012. Epub 2008 Mar 26.
6
Using microarrays to study the microenvironment in tumor biology: the crucial role of statistics.
Semin Cancer Biol. 2008 Oct;18(5):305-10. doi: 10.1016/j.semcancer.2008.03.001. Epub 2008 Mar 26.
7
Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests.
J Med Screen. 2008;15(1):18-22. doi: 10.1258/jms.2008.007076.
8
Morphogens, morphostats, microarchitecture and malignancy.
Nat Rev Cancer. 2007 Jun;7(6):464-74. doi: 10.1038/nrc2146.
9
Identifying genes that contribute most to good classification in microarrays.
BMC Bioinformatics. 2006 Sep 7;7:407. doi: 10.1186/1471-2105-7-407.
10
Design of cancer screening trials/randomized trials for evaluation of cancer screening.
World J Surg. 2006 Jul;30(7):1152-62. doi: 10.1007/s00268-006-0074-9.
Zotero 插件